Initial serum MMP-9 activity as a bad prognostic factor after ischemic stroke

Authors

  • Jacek Kurzepa Department of Biochemistry and Molecular Biology, Medical University of Lublin Author
  • Joanna Bielewicz Department of Neurology, University Hospital No. 4 in Lublin Author
  • Paweł Kurczab Department of Chemotherapy, Specialistic Hospital in Brzozów Author
  • Zbigniew Stelmasiak Department of Neurology, University Hospital No. 4 in Lublin Author
  • Andrzej Stepulak Department of Biochemistry and Molecular Biology, Medical University of Lublin Author

Keywords:

stroke scales, MMP-2, MMP-9

Abstract

An early evaluation of ischemic stroke (IS) biomarkers enhances the chance for proper diagnosis and can predict the clinical outcome after acute phase of the disease. Our purpose was to evaluate the MMP-2 and MMP-9 serum activity as the prognostic factors for patients’ disability after IS. Finally, twenty patients with IS confirmed in computed tomography scans were prospectively enrolled into the study. The patients were examined by functional disability scales: Barthel Index (BI) and Modified Rankin Scale (mRS) at the admission and after 3 months from IS onset. The serum MMP-2 and MMP-9 activities were measured on the first day of stroke with use of gelatin zymography. BI scores increased and mRS decreased significantly after 3 months from the stroke onset in comparison with day 1 (p<0.05). Significant relationships between serum MMP-9 activity and late BI (r=-0.63, p=0.003) or mRS (r=0.67, p=0.002) scores, estimated at three months from the stroke, were noticed. In addition, we observed significant correlation between initial MMP-2 serum activity and late BI (r=-0.45, p=0.05). Our data indicated on serum MMP-9 rather than MMP-2 measured during acute phase of IS as a predictor of patients’ functional status three months after the stroke.

References

1. Wang X.C., Gao P.Y., Lin Y., Ma L., Guan-ruiLiu, Xue J., Sui B.B., Wang C.J., Wang Y.J. Clinical value of computed tomography perfusion source images in acute stroke. Neurol. Res., 2009; 31: 1079-1083.

2. Chandler S., Miller K.M., Clemens J.M., Lury J., Corkill D., Anthony D.C., Adams S.E., Gearing A.J. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J. Neuroimmunol., 1997; 72: 155-161.

3. Hartung H.P., Kieseier B.C. The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J. Neuroimmunol., 2000; 107: 140-147.

4. Uhm J.H., Dooley N.P., Villemure J.G., Yong V.W. Mechanisms of glioma invasion: role of matrix-metalloproteinases. Can. J. Neurol. Sci., 1997; 24: 3-15.

5. Jung S., Moon K.S., Kim S.T., Ryu H.H., Lee Y.H., Jeong Y.I., Jung T.Y., Kim I.Y., Kim K.K., Kang S.S. Increased expression of intracystic matrix metalloproteinases in brain tumors: relationship to the pathogenesis of brain tumor-associated cysts and peritumoral edema. J. Clin. Neurosci., 2007; 14: 1192-1198.

6. Planas A.M., Sole S., Justica C. Expression and Activation of Matrix Metalloproteinase-2 and -9 in Rat Brain after Transient Focal Cerebral Ischaemia. Neurobiol. Dis., 2001; 8: 834-846.

7. Castillo J., Rodriguez I. Biochemical Changes and Inflammatory Response as Markers for Brain Ischemia: Molecular Markers of Diagnostic Utility and Prognosis in Human Clinical Practice. Cerebrovasc. Dis., 2004; 17 Suppl.1: 7-18.

8. Kurzepa J., Szczepańska-Szerej A., Stryjecka-Zimmer M., Malecka- Massalska T., Stelmasiak Z. Simvastatin could prevent increase of the serum MMP-9/TIMP-1 ratio in acute ischaemic stroke. Folia. Biol. (Praha), 2006; 52: 181-183.

9. Shigemori Y., Katayama Y., Mori T., Maeda T., Kawamata T. Matrix metalloproteinase-9 is associated with blood-brain barrier opening and brain edema formation after cortical contusion in rats. Acta. Neurochir. Suppl., 2006; 96: 130-3.

10. Petty M.A., Wettstein J.G. Elements of cerebral microvascular ischaemia. Brain Res. Rev., 2001; 36: 23-34.

11. Opdenakker G., Van den Steen P.E., Van Damme J. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol., 2001; 22: 571-579.

12. Chandler S., Coates R., Gearing A., Lury J., Wells G., Bone E. Matrix metalloproteinases degrade myelin basic protein. Neurosci. Lett., 1995; 201: 223-6.

13. Castellanos M., Leira R., Serena J., Pumar J.M., Lizasoain I., Castillo J., Davalos A. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke, 2003; 34: 40-46.

14. Lucivero V., Prontera M., Mezzapesa D.M., Petruzzellis M., Sancilio M., Tinelli A., Di Noia D., Ruggieri M., Federico F.. Different roles of matrix metalloproteinases-2 and -9 after human ischaemic stroke. Neurol. Sci., 2007; 28: 165-170.

15. Kurzepa J., Stryjecka-Zimmer M. The effect of interferon beta-1a on MMP- 2 and MMP-9 proteolytic activity. Folia Biol. (Praha), 2007; 53: 220-221.

16. Loewen S.C., Anderson B.A. Predictors of stroke outcome using objective measurement scales. Stroke, 1990; 21: 78-81.

17. Kurzepa J., Bielewicz J., Czekajska-Chehab E., Kurzepa J., Bartosik-Psujek H., Grabarska A., Stelmasiak Z. CT volume/density ratio as the marker of ischaemic brain injury. Acta Neurol. Scand., 2010; 2: in press.

Downloads

Published

2011-05-19

Issue

Vol. 12 No. 1 (2011): Current Problems of Psychiatry

Section

Artykuły

License

Copyright (c) 2011 Authors

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.

How to Cite

Kurzepa, J., Bielewicz, J., Kurczab, P., Stelmasiak, Z., & Stepulak, A. (2011). Initial serum MMP-9 activity as a bad prognostic factor after ischemic stroke. Current Problems of Psychiatry, 12(1), 38-40. https://czasopisma.umlub.pl/cpp/article/view/2123